Prognostic Value of the Lung Immune Prognostic Index in Patients with Untreated Advanced Renal Cell Carcinoma (arcc) Receiving Nivolumab Plus Ipilimumab (N+I) or Sunitinib (SUN) in the CheckMate 214 Trial.
Journal of Clinical Oncology（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要